JP7200238B2 - グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針 - Google Patents

グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針 Download PDF

Info

Publication number
JP7200238B2
JP7200238B2 JP2020519850A JP2020519850A JP7200238B2 JP 7200238 B2 JP7200238 B2 JP 7200238B2 JP 2020519850 A JP2020519850 A JP 2020519850A JP 2020519850 A JP2020519850 A JP 2020519850A JP 7200238 B2 JP7200238 B2 JP 7200238B2
Authority
JP
Japan
Prior art keywords
glp
analogue
pharmaceutical composition
treatment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020519850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523420A5 (https=
JP2020523420A (ja
Inventor
ソンネ，キム
モウリツェン，ウルリーク
グレルプ，ペーター
イェッペセン，パレ・ベッケル
Original Assignee
ジーランド・ファルマ・アー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62748940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7200238(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1709643.9A external-priority patent/GB201709643D0/en
Priority claimed from GBGB1714203.5A external-priority patent/GB201714203D0/en
Priority claimed from GBGB1800873.0A external-priority patent/GB201800873D0/en
Application filed by ジーランド・ファルマ・アー／エス filed Critical ジーランド・ファルマ・アー／エス
Publication of JP2020523420A publication Critical patent/JP2020523420A/ja
Publication of JP2020523420A5 publication Critical patent/JP2020523420A5/ja
Priority to JP2022203265A priority Critical patent/JP7566859B2/ja
Application granted granted Critical
Publication of JP7200238B2 publication Critical patent/JP7200238B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2020519850A 2017-06-16 2018-06-15 グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針 Active JP7200238B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022203265A JP7566859B2 (ja) 2017-06-16 2022-12-20 グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1709643.9A GB201709643D0 (en) 2017-06-16 2017-06-16 Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues
GB1709643.9 2017-06-16
GBGB1714203.5A GB201714203D0 (en) 2017-09-05 2017-09-05 Dosage regimes for the administration of Glucagon-Like Peptide-2(GLP-2)Analogues
GB1714203.5 2017-09-05
GBGB1800873.0A GB201800873D0 (en) 2018-01-19 2018-01-19 Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues
GB1800873.0 2018-01-19
PCT/EP2018/065951 WO2018229252A1 (en) 2017-06-16 2018-06-15 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022203265A Division JP7566859B2 (ja) 2017-06-16 2022-12-20 グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針

Publications (3)

Publication Number Publication Date
JP2020523420A JP2020523420A (ja) 2020-08-06
JP2020523420A5 JP2020523420A5 (https=) 2021-07-26
JP7200238B2 true JP7200238B2 (ja) 2023-01-06

Family

ID=62748940

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020519850A Active JP7200238B2 (ja) 2017-06-16 2018-06-15 グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針
JP2022203265A Active JP7566859B2 (ja) 2017-06-16 2022-12-20 グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022203265A Active JP7566859B2 (ja) 2017-06-16 2022-12-20 グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針

Country Status (19)

Country Link
US (3) US20200000883A1 (https=)
EP (3) EP4424362A3 (https=)
JP (2) JP7200238B2 (https=)
KR (2) KR102504200B1 (https=)
CN (2) CN118526577A (https=)
AU (2) AU2018285580B2 (https=)
BR (1) BR112019026711A2 (https=)
CA (1) CA3066523A1 (https=)
CL (1) CL2019003660A1 (https=)
CO (1) CO2019014028A2 (https=)
DK (2) DK3638291T3 (https=)
ES (2) ES2894629T3 (https=)
IL (2) IL299864B2 (https=)
MX (2) MX2019015054A (https=)
PE (1) PE20200678A1 (https=)
SG (1) SG11201912161SA (https=)
TW (1) TWI791539B (https=)
WO (1) WO2018229252A1 (https=)
ZA (2) ZA201908355B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019026711A2 (pt) 2017-06-16 2020-06-30 Zealand Pharma A/S regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2)
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN111560061A (zh) * 2020-05-26 2020-08-21 成都圣诺生物制药有限公司 一种Gelpaglutide的制备方法
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
MX2023006901A (es) 2020-12-16 2023-06-26 Zealand Pharma As Uso de analogos de glp-2 en pacientes con insuficiencia renal.
AU2022341538A1 (en) 2021-09-10 2024-04-11 Zealand Pharma A/S Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues
WO2023118416A1 (en) 2021-12-23 2023-06-29 Zealand Pharma A/S Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues
WO2023132609A1 (ko) * 2022-01-05 2023-07-13 주식회사 휴온스랩 지속형 지방산-펩타이드 유도체 및 이의 용도
KR20240145523A (ko) * 2022-02-24 2024-10-07 엔테라 바이오 리미티드 글루카곤 유사 펩타이드-2의 경구 투여를 위한 산 중화 중합체를 포함하는 제형
EP4572783A1 (en) 2022-09-30 2025-06-25 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs)
IL322328A (en) 2023-01-27 2025-09-01 Zealand Pharma As Glucagon-like peptide-2 (GLP-2) analogs and their medical uses for the treatment of short bowel syndrome (SBS)
CN116478269A (zh) * 2023-04-28 2023-07-25 成都奥达生物科技有限公司 一种长效替度鲁肽化合物
WO2025141129A1 (en) 2023-12-28 2025-07-03 Zealand Pharma A/S Formulations of glucagon-like-peptide 2 (glp-2) analogues and their uses
WO2025181330A1 (en) * 2024-02-29 2025-09-04 Vectivbio Ag Dosage regimens for glucagon-like peptide 2 (glp-2) analogs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518941A (ja) 2004-11-01 2008-06-05 エヌピーエス アレリックス コーポレーション 大腸連続性を伴う短腸症候群患者の治療
JP2008539713A (ja) 2005-05-04 2008-11-20 ジーランド ファーマ アクティーゼルスカブ グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2961045B2 (ja) 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5912229A (en) 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
DE69717092T2 (de) 1996-03-01 2003-07-24 Novo Nordisk A/S, Bagsvaerd Gebrauch einer pharmazeutischen Zusammensetzung, enthaltend ein appetitzügelndes Peptid
DE60142885D1 (de) 1996-04-12 2010-10-07 Ontario Inc 1149336 Dem Glukagon ähnliches Peptid-2
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
US20020025933A1 (en) 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US5952301A (en) 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
US6051557A (en) 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
DK0981362T3 (da) 1997-05-16 2004-03-15 Ontario Inc 1149336 Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal
AU766219B2 (en) 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
JP4394279B2 (ja) 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
WO1999058144A1 (en) 1998-05-11 1999-11-18 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2001041779A2 (en) 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
ES2310192T3 (es) 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
ATE396202T1 (de) 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
US7144863B2 (en) 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
EP1562626B1 (en) 2002-10-29 2007-11-28 ALZA Corporation Stabilized, solid-state polypeptide particles
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
TR201906789T4 (tr) 2003-11-20 2019-05-21 Novo Nordisk As Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
EP1727560B1 (en) 2004-01-27 2012-09-12 Kyowa Hakko Kirin Co., Ltd. Gastrointestinal proliferative factor and uses thereof
WO2005082404A2 (en) 2004-02-27 2005-09-09 Novo Nordisk A/S Glp-2 derivatives modified by lipophilic substituents
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
CN101331224A (zh) * 2005-10-24 2008-12-24 森托科尔公司 Glp-2模拟体、多肽、组合物、方法和用途
CN101341254A (zh) 2005-12-24 2009-01-07 蒂加斯克乳制品研究中心 反-10，顺-12十八碳二烯酸的生产方法
US20090028832A1 (en) 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
AU2007319066B2 (en) 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
WO2008082656A1 (en) 2006-12-29 2008-07-10 Ipsen Pharma S.A.S. Glp-1 pharmaceutical compositions
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2300037B1 (en) 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
US8685919B2 (en) 2008-12-15 2014-04-01 Zealand Pharma A/S Glucagon analogues
CN102325539A (zh) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
CN101824087A (zh) 2009-03-05 2010-09-08 连云港恒邦医药科技有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2552952A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
CA2798518A1 (en) 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
CN102212127B (zh) 2011-05-17 2015-02-04 上海景泽生物技术有限公司 胰高血糖素样肽-2聚乙二醇结合物及其制备方法和用途
KR20240110072A (ko) 2011-05-18 2024-07-12 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
EP2755675B1 (en) * 2011-09-12 2018-06-06 Amunix Operating Inc. Glucagon-like peptide-2 compositions and methods of making and using same
AU2013255752B2 (en) 2012-05-03 2017-11-09 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
AU2013295035B2 (en) 2012-07-23 2017-08-03 Zealand Pharma A/S Glucagon analogues
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US20160067311A1 (en) * 2014-09-10 2016-03-10 Helsinn Healthcare Sa Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
AU2015335743B2 (en) 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
WO2016102683A1 (en) 2014-12-23 2016-06-30 Camurus Ab Controlled-release formulations
EA034820B1 (ru) 2015-02-17 2020-03-25 Эли Лилли Энд Компани Порошковый состав для интраназального введения для лечения гипогликемии
WO2017053822A1 (en) 2015-09-23 2017-03-30 Behavioral Recognition Systems, Inc. Detected object tracker for a video analytics system
EP4591853A1 (en) 2016-11-21 2025-07-30 Amylyx Pharmaceuticals, Inc. Buffered formulations of exendin (9-39)
AU2017371516C1 (en) 2016-12-09 2021-09-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
WO2018142363A1 (en) 2017-02-06 2018-08-09 Orbicular Pharmaceutical Technologies Private Limited Ready to use compositions of glp-2 analogues through self-administrable devices
BR112019026711A2 (pt) 2017-06-16 2020-06-30 Zealand Pharma A/S regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2)
GB201710822D0 (en) 2017-07-05 2017-08-16 Zealand Pharma As Methods and medical uses relating to the treatment of hypoglycaemia
WO2019110838A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
EP3628683A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3924369A1 (en) * 2019-02-11 2021-12-22 OPKO Biologics Ltd. Long-acting glp-2 analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518941A (ja) 2004-11-01 2008-06-05 エヌピーエス アレリックス コーポレーション 大腸連続性を伴う短腸症候群患者の治療
JP2008539713A (ja) 2005-05-04 2008-11-20 ジーランド ファーマ アクティーゼルスカブ グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLoS ONE，2012年，7(11): e50630，doi:10.1371/journal.pone.0050630

Also Published As

Publication number Publication date
ES2894629T3 (es) 2022-02-15
KR102504200B1 (ko) 2023-02-28
AU2018285580B2 (en) 2024-05-09
DK3881861T3 (da) 2024-09-09
TW201904607A (zh) 2019-02-01
TWI791539B (zh) 2023-02-11
IL271245B1 (en) 2023-06-01
BR112019026711A2 (pt) 2020-06-30
PE20200678A1 (es) 2020-06-11
JP2020523420A (ja) 2020-08-06
CO2019014028A2 (es) 2020-04-01
KR20200020817A (ko) 2020-02-26
AU2018285580A1 (en) 2020-01-30
EP3638291A1 (en) 2020-04-22
EP3638291B1 (en) 2021-08-18
DK3638291T3 (da) 2021-10-18
ZA201908355B (en) 2024-06-26
KR102754148B1 (ko) 2025-01-15
RU2019142586A (ru) 2021-07-16
WO2018229252A1 (en) 2018-12-20
ZA202402068B (en) 2024-11-27
US12297251B1 (en) 2025-05-13
IL271245A (en) 2020-01-30
CL2019003660A1 (es) 2020-05-04
EP4424362A3 (en) 2024-11-27
MX2023003828A (es) 2023-04-13
ES2989204T3 (es) 2024-11-25
IL299864B2 (en) 2024-06-01
CA3066523A1 (en) 2018-12-20
IL299864B1 (en) 2024-02-01
EP3881861A1 (en) 2021-09-22
AU2024202486B2 (en) 2024-07-18
JP2023036769A (ja) 2023-03-14
IL299864A (en) 2023-03-01
CN111032072A (zh) 2020-04-17
JP7566859B2 (ja) 2024-10-15
CN118526577A (zh) 2024-08-23
KR20230035677A (ko) 2023-03-14
EP4424362A2 (en) 2024-09-04
MX2019015054A (es) 2020-02-13
IL271245B2 (en) 2023-10-01
EP3881861B1 (en) 2024-07-31
US20250136655A1 (en) 2025-05-01
US20250136657A1 (en) 2025-05-01
SG11201912161SA (en) 2020-01-30
US20200000883A1 (en) 2020-01-02
AU2024202486A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
JP7566859B2 (ja) グルカゴン様ペプチド２（ｇｌｐ－２）類似体の投与の投薬方針
KR101200227B1 (ko) 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
RU2785662C9 (ru) Схемы дозирования для введения аналогов глюкагоноподобного пептида 2 (гпп-2)
RU2785662C2 (ru) Схемы дозирования для введения аналогов глюкагоноподобного пептида 2 (гпп-2)
CA3202157A1 (en) Use of glp-2 analogues in patients with renal insufficiency
HK40113969A (en) Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
HK40059738A (en) Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
HK40059738B (en) Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
HK40017010A (en) Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
HK40017010B (en) Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221221

R150 Certificate of patent or registration of utility model

Ref document number: 7200238

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250